fgfr4 kinase  (Carna Inc)

Journal: Journal of Translational Medicine

Article Title: Limonin attenuates hyperlipidemia by regulating the gut microbiota-bile acid-farnesoid X receptor axis

doi: 10.1186/s12967-026-07826-7

Figure Lengend Snippet: Impacts of Limonin upon FXR/FGF15 signaling pathway in hyperlipidemia mice liver. ( A ) mRNA expression levels of fgf15 in liver. ( B ) mRNA expression levels of Fgfr4 in liver. ( C ) mRNA expression levels of Cyp7a1 in liver. ( D ) Representative picture of immunofluorescence expression in mice liver. ( E ) F Immunofluorescence expression of CYP7A1 in liver. ( F ) Immunofluorescence expression of CYP7A1 in liver. ( G ) Immunofluorescence expression of CYP7A1 in liver. ( H ) FGF15 protein expression levels. ( I ) FGFR4 protein expression levels. ( J ) CYP7A1 protein expression levels. ( K ) Representative protein bands detected by WB. Values are denoted by mean ± SD ( n = 3). # P < 0.05, ## P < 0.01 vs. MG and * P < 0.05, ** P < 0.01 vs. NG

Article Snippet: Following blocking in 5% skim milk for 2 h at room temperature, we cultured culture membrane with primary antibody including FXR1 (BOSTER, M03308), FGF15(CUSABIO, O35622 ), ASBT (Cohesion, CQA5895), CYP7A1 (Proteintech, 18054-1-AP), and FGFR4 (BOSTER, BM5163), β-actin (AB_2750915, CPA9121) overnight at 4 °C, followed by reaction of enzyme-labeled secondary antibody for 2 h at room temperature.

Techniques: Expressing, Immunofluorescence

Journal: Journal of Translational Medicine

Article Title: Limonin attenuates hyperlipidemia by regulating the gut microbiota-bile acid-farnesoid X receptor axis

doi: 10.1186/s12967-026-07826-7

Figure Lengend Snippet: Graphical illustration of mechanism mediating anti-hyperlipidemia effects of Limonin. The possible mechanisms by which limonin alleviates dyslipidemia are as follows: (1) Reduced relative abundance of BSH-producing microbes induced by Limonin. (2) Boosted conjugated BAs, particularly TCA, T-αMCA, and T-βMCA acting in antagonistic manner on intestinal FXR, (3) The increased conjugated BAs boosted elimination of BAs via feces, and also as endogenous signaling molecules that inhibited activation of intestinal FXR causing FGF15’s reduced production in the distal ileum. (4) The FGF15 through the enterohepatic circulation to enter mice liver, and regulates liver CYP7A1 expression via negative feedback of FGF15-FGFR4 pathway to promoting the synthesis of TC to BA, thereby reducing TC

Article Snippet: Following blocking in 5% skim milk for 2 h at room temperature, we cultured culture membrane with primary antibody including FXR1 (BOSTER, M03308), FGF15(CUSABIO, O35622 ), ASBT (Cohesion, CQA5895), CYP7A1 (Proteintech, 18054-1-AP), and FGFR4 (BOSTER, BM5163), β-actin (AB_2750915, CPA9121) overnight at 4 °C, followed by reaction of enzyme-labeled secondary antibody for 2 h at room temperature.

Techniques: Activation Assay, Expressing